On Nov 08, major Wall Street analysts update their ratings for $Sarepta Therapeutics (SRPT.US)$, with price targets ranging from $150 to $209.
Morgan Stanley analyst Michael Ulz maintains with a buy rating, and maintains the target price at $200.
Barclays analyst Gena Wang maintains with a buy rating, and maintains the target price at $209.
Evercore analyst Gavin Clark-Gartner maintains with a buy rating, and adjusts the target price from $179 to $170.
TD Cowen analyst Ritu Baral maintains with a buy rating, and maintains the target price at $203.
Guggenheim analyst Debjit Chattopadhyay maintains with a buy rating, and sets the target price at $150.
Furthermore, according to the comprehensive report, the opinions of $Sarepta Therapeutics (SRPT.US)$'s main analysts recently are as follows:
Sarepta reported significant third-quarter earnings, surpassing expectations for both total and Elevidys revenue. Analyst commentary suggests that Sarepta's consistent guidance for Elevidys may seem understated.
Sales of Elevidys and the exon-skipping franchise exceeded expectations, and the management's forecast for Q4 Elevidys remains steady, suggesting the possibility of surpassing predictions provided holiday disruptions remain low. There is a potential for a positive adjustment to the full-year guidance for 2025 come January, yet the current market valuation seems to reflect a five-year trajectory toward the end of exclusivity.
Sales of Elevidys experienced better-than-anticipated growth in the third quarter, accompanied by optimistic commentary from management regarding the product's launch. Analysts believe that all indications suggest the potential for Elevidys to become a multi-billion-dollar product, with the prospects of being augmented by a series of gene therapy introductions in the upcoming five years.
Here are the latest investment ratings and price targets for $Sarepta Therapeutics (SRPT.US)$ from 9 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月8日，多家華爾街大行更新了$Sarepta Therapeutics (SRPT.US)$的評級，目標價介於150美元至209美元。
摩根士丹利分析師Michael Ulz維持買入評級，維持目標價200美元。
巴克萊銀行分析師Gena Wang維持買入評級，維持目標價209美元。
Evercore分析師Gavin Clark-Gartner維持買入評級，並將目標價從179美元下調至170美元。
TD Cowen分析師Ritu Baral維持買入評級，維持目標價203美元。
Guggenheim分析師Debjit Chattopadhyay維持買入評級，目標價150美元。
此外，綜合報道，$Sarepta Therapeutics (SRPT.US)$近期主要分析師觀點如下：
Sarepta報告了顯著的第三季度收入，超過了對總營業收入和Elevidys收入的預期。分析師評論指出，Sarepta對Elevidys的一貫指導可能看起來有些保守。
Elevidys和exon-skipping系列的銷售超出預期，管理層對第四季度Elevidys的預測保持穩定，暗示如果假日干擾保持較低，可能超越預期。到了一月，可能會對2025年全年指引進行積極調整，然而當前市場估值似乎反映了在專利期末朝着五年軌跡發展。
第三季度Elevidys的銷售出現超出預期的增長，管理層對產品發佈的樂觀評論。分析師認爲所有跡象表明Elevidys有望成爲一個價值數十億美元的產品，未來五年有望受一系列基因治療介紹的增強。
以下爲今日9位分析師對$Sarepta Therapeutics (SRPT.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
